



Biomedicine and Molecular Biosciences (BMBS)

BM1206- Cooperation Studies on Inherited Susceptibility to Colorectal Cancer

Inga Dadeshidze

2nd MC Meeting, Edinburgh, 21 October 2013

 COST is supported by the EU Framework Programme

 ESF provides the COST Office through a European Commission contract



Domain BMBS

Biomedicine and Molecular Biosciences (BMBS)



35 running Actions
 BMBS covers all areas of medicine as practiced in Europe from **basic** and **preclinical** to **clinical research** developed to translate the “**bench to bedside**” concept. 2

 **cost**
 EUROPEAN COOPERATION IN SCIENCE AND TECHNOLOGY

News from COST – BMBS (1)

oc-2012-2 BMBS Domain – New Actions

5 BMBS proposals have been approved by the CSO and will start their activities this Autumn

Code	Title	CSO App.	+M	Proposer	Parties
BM1301	Aldosterone and mineralocorticoid receptor: Pathophysiology, clinical implication and therapeutic innovations (ADMIRE)	2013/05/16	3	Frédéric JAISSE frederic.jaisser@inserm.fr	12
BM1302	Joining Forces in Corneal Regeneration Research	2013/05/16	3	claus.cursiefen@uk-koeln.de	9
BM1303	A systematic elucidation of differences of sex development (DSDnet)	2013/05/16	3	Olaf Hiort Olaf.hiort@uksh.de	13
BM1304	Applications of MR imaging and spectroscopy techniques in neuromuscular disease: collaboration on outcome measures and pattern recognition for diagnostics and therapy development	2013/05/16	3	Volker Straub volker.straub@ncl.ac.uk	9
BM1305	Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies (A FACTT)	2013/05/16	3	Eva Maria Martínez Cáceres emmartinez.liradbst.germanstria3s@gencat.cat	14
TD1301	Development of a European-based Collaborative Network to Accelerate Technological, Clinical and Commercialisation Progress in the Area of Medical Microwave Imaging	2013/05/16	3	TBA / TD SO Mafalda Quintas	15
TD1303	European Network for Neglected Vectors and Vector-Borne Infections (EURNEGVEC)	2013/05/16	3	TBA / TD SO Mafalda Quintas	25


• http://www.cost.eu/domains_actions/bmbs/Actions

Contact your CNC to join the MC, contact Action Chair to join the WGs




BM1301 – Aldosterone and mineralocorticoid receptor: Pathophysiology, clinical implication and therapeutic innovations (ADMIRE)

- A pleiotropic system with major health impact
- A therapeutic target
- Knowledge sharing between experts
- Cross-disciplinary working
- Enhance partnership with industry/SME
- Increase relationship with third countries




Interested Countries: 10

Proposer: FR
AT, CH, DE, ES, IE,
IT, NL, PL, UK




BM1302 – Joining Forces in Corneal Regeneration Research

- 10 millions people suffer from corneal blindness but only 1%/year of corneal transplantation
- Development of biodegradable artificial corneas
- Combine scientific, clinical and industrial knowledge
- Basic research to clinical application
- Development of a new generation of cornea specialists (ophthalmology)




Interested Countries: 6
 Proposer: DE
 BE, DK, NL, SE, UK




5

BM1303 – A systematic elucidation of differences of sex development (DSDnet)

- Inborn discrepancy in sex development
- Complex management and prognosis
- Challenges of concepts of sex and gender
- Link leading international scientists, clinicians and stakeholders
- Benefit the science in rare diseases
- Formation of a European Reference Network



Interested Countries: 13
 Proposer: IT
 AT, BE, BG, CH, DK, ES, FI, FR, IT, NL, PL, SE, SI, UK




6

COST
 EUROPEAN COOPERATION IN SCIENCE AND TECHNOLOGY

BM1304 – Applications of MR imaging and spectroscopy techniques in neuromuscular disease: collaboration on outcome measures and pattern recognition for diagnostics and therapy developments


- Diagnosis and therapy development for NMD
- Monitor disease progression and treatment effect
- MRI and MRS techniques
- Sharing of expertise and data
- Development of an online atlas of muscle MRI and MRS
- Enhance knowledge of scientists and healthcare professionals



cost
EUROPEAN COOPERATION IN SCIENCE AND TECHNOLOGY

Interested Countries: 11


Proposer: UK
BE, CH, DE, DK, EL,
FI, FR, IT, NL, PL



7

BM1305 – Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies (A FACTT)


- Generation of novel immunotherapies
- Effective and safer therapies
- Restrain unwanted immune reactions long-term
- Initiate network to coordinate European CTT efforts
- Establishment of consensus monitoring parameters



cost
EUROPEAN COOPERATION IN SCIENCE AND TECHNOLOGY

Interested Countries: 10

Proposer: ES
AT, CH, DE, FR, IE,
IT, NL, PL, UK



8



News from COST – BMBS (3)

First Open Call of 2013 – oc-2013-1

Out of the total of **612** proposals submitted for this call, **99** were submitted for the BMBS Domain.

20 were selected and evaluated at the BMBS EEP panel on 5-6 September.

10 were selected to submit a full proposal at the DC Hearings on 23 September 2013.

The approved actions from this Open Call will start in Spring 2014.

Second Open Call of 2013 – oc-2013-2

9



COST Open Call

Outcome of the 15th Collection
OC-2013-2 (27/09/2013)

BMBS	FA	FPS	MPNS	CMST	ESSE M	ICT	TUD	ISCH	Totals
121	72	17	46	23	85	81	56	231	732

The **collection 2013-2** is closed since Friday September 27, 5 pm
100 more compared to previous collection
BMBS - 22 more proposals

10



News from COST – BMBS (4)

Next BMBS APC / DC MEETING

The BMBS APC / DC meeting will hold in Malta on 28, 29 and 30 April 2014

- Action Chair must attend to present the Action to the DC

11



Action Information (1)

CSO approval: 21/11/2012
Start of Action: 30/04/2013
End of Action: 29/04/2017
Duration: 4 years
Parties: 17
MC Chair: [Dr Sergi CASTELLVI-BEL](#) (ES)
MC Vice Chair: [Prof Annika LINDBLOM](#) (SE)
DC Rapporteur: [Dr Ursula GUNDERT-REMY](#) (DE)

12



Action Information (2)

Budget GP1: **86, 000.00 EUR**
Duration of GP1: 01/06/2013 to 31/05/2014

Planned activities:

- **Meetings**
 - Core group
 - joint MC/WG Meetings
 - Meeting and TRANSLATIONAL GENOMICS IN BIOMEDICINE Workshop
- **4 STSMs** **for 2nd GP Training school**
- **Dissemination**
 - Website
 - Publications

13



MONITORING PROGRESS REPORT

- ***I. Management Report prepared by the Grant Holder***
- ***II. Scientific Report prepared by the Chair of the Management Committee of the Action***
- ***III. Previous versions of the Scientific Report; i.e., part II of past reporting periods***


14



MONITORING PROGRESS REPORT


II. Scientific Report

- Results versus objectives
- *II.A. Innovative networking*
- *II.B. Inter-disciplinary networking*
- *II.C. New networking*
- *II.D. Self evaluation*



Ending an Action: General points


- Training schools and STSMs can only take place within the lifetime of the Action
- A Final Meeting is a wrap-up of the Action's activities and signals the end of the Action
- The Final publication is paid from the General COST budget, not from the Action's budget



Ending an Action: Final Meeting

Before the Final Meeting:

- 6 months in advance, date and location to be agreed with SO and Rapporteurs
- at least 2 weeks prior to the Final Meeting, a draft Final Scientific and Financial Report to be submitted to the Expert Panel.
- Expert panel (DC Rapporteur, SO, 1-2 external experts)
- No other activities are permitted after the Final Meeting.



Ending an Action: Final Meeting

During the Final Meeting:

- general Action presentation - MC Chair
- budget allocation and implementation overview – GH
- WG progress reports – WG leaders
- Rapporteurs's reports – 2 DC Rapporteurs
- For complete details, see Vademecum – 1.4.2. **Action final assessment and final scientific report** (page 12)

Ending an Action: Final Evaluation Report

- **I. Management Report**
prepared by the Grant Holder
- **II. Final Scientific Report**
prepared by the Chair of the Management Committee (using cumulative Monitoring Progress Report template) within **4 months** after the end of the Action
- **III. Evaluation Report**
prepared by the Evaluation Panel established by the Domain Committee and edited by the Rapporteur
- **IV. DC Remarks**
prepared by the Domain Committee

Ending an Actions: what you are evaluated on

- Results versus objectives
- Innovative networking
- Inter-disciplinary networking
- New networking
- Coordination and management
- Strengths and weaknesses

Ending an Actions: Final Publication

Amount:

The COST Office will finance the **final publication for an amount of up to 10.000€** (excl. VAT)

Steps to be followed:

1. MC decision and official request from Chair to SO at the latest 6 months before the official end date of the Action
2. SO approval
3. Validation of request by COST Head of Communication
4. Publisher offer sent via the MC chair
5. Purchase Order
6. Print release
7. Delivery and Payment.

For complete details, see Vademecum – 8.2. Final Action publication (page 43)

Ending an Actions: Final Publication

Eligible costs:

- production and distribution cost of a publication by a printing house or for the creation and/or distribution of alternative dissemination tools,
- purchase and distribution of a fixed number of copies of high-quality publications produced by a renowned publisher (usually books or journals);
- proofreading, editing, production and distribution costs relating to the production of publications and dissemination tools;

Non-eligible costs:

- graphic design
- translation

COST Office Contacts

- **Science Officer:**
Dr. Inga Dadeshidze
inga.dadeshidze@cost.eu
Tel: + 32 (2) 533 3817
- **Administrative Officer:**
Ms Jeannette Nchung Oru
jeannette.nchungoru@cost.eu
- **COST website:**
www.cost.eu
- **Action COST website:**
http://www.cost.eu/domains_actions/bmbs/Actions/BM1208

23

www.cost.eu

Domain pages: e.g. www.cost.eu/bmbs	Reciprocal Agreements: www.cost.eu/about_cost/reciprocal_agreements
Open Call: www.cost.eu/opencall	Library: www.cost.eu/library
Guidelines: www.cost.eu/guidelines	Events: www.cost.eu/events
FAQ: www.cost.eu/service/faq	Access to e-COST: https://e-services.cost.eu/

e-COST related mails should be sent to: e-cost@cost.eu

ACRONYMS (1/2)

AO	Administrative Officer
APC	Annual Progress Conference
BMBS	Biomedicine and Molecular Biosciences (Domain)
CGA	COST Grant Agreement
CGS	COST Grant System
CG	Core Group
CMST	Chemistry and Molecular Sciences and Technologies (Domain)
CNC	COST National Coordinator
CSO	Committee of Senior Officials
DC	Domain Committee
DCCCCM	Domain Committee Chairs Cluster Consensus Meeting
EEP	External Experts Panel
ESF	European Science Foundation
ESR	Early Stage Researcher
ESSEM	Earth System Science and Environmental Management (Domain)
FA	Food and Agriculture (Domain)
FPS	Forests, their Products and Services (Domain)
GH	Grant Holder
HOSO	Head Of Science Operations

ACRONYMS (2/2)

ICT	Information and Communication Technologies (Domain)
IE	Interdisciplinary Exploratoria
ISCH	Individuals, Societies, Cultures and Health (Domain)
JAF	Judiciaire, Administratif, Financière, Working party of Legal, Administrative and Financial Affairs within COST (CSO Executive Group)
JSO	Junior Science Officer
MC	Management Committee
MoU	Memorandum of Understanding
MPNS	Materials, Physical and Nanosciences (Domain)
SAO	Senior Administration Officer
SO	Science Officer
SSO	Senior Science Officer
STSM	Short-Term Scientific Mission
TD	Trans-Domain
TDP	Trans-Domain Proposal
TDP-SAB	Trans-Domain Proposal Standing Assessment Body
ToR	Terms of Reference
TUD	Transport and Urban Development (Domain)
WG	Working Group



COST News by e-mail?
Sign up at <http://www.cost.eu/notification>



<http://www.facebook.com/COST.Programme>



<http://twitter.com/COSToffice>



<http://www.linkedin.com/groupRegistration?gid=1699127>

COST Office
Avenue Louise 149
1050 Brussels, Belgium
T: +32 (0)2 533 3833
F: +32 (0)2 533 3890
office@cost.eu

www.cost.eu